PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Data for Prothena's NEOD001 to be Presented at the 58th Annual American Society of Hematology Meeting
DUBLIN, Ireland, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its NEOD001 Phase 1/2
View HTML
Toggle Summary Prothena Reports Third Quarter 2016 Financial Results and Provides R&D Update
Net cash used in operating and investing activities was $39.1 million in the third quarter and  $96.8 million for the first nine months of 2016; quarter-end cash and restricted cash position of $412.6 million supports advancement of a diverse pipeline and commercial capabilities Appointed Gene G.
View HTML
Toggle Summary Prothena to Report Third Quarter 2016 Financial Results on November 1
DUBLIN, Ireland, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the third quarter and first nine
View HTML
Toggle Summary Prothena Announces Appointment of Dr. Gene G. Kinney as President, Chief Executive Officer and Director
DUBLIN, Ireland, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that Gene Kinney, PhD has been appointed President and
View HTML
Toggle Summary In Memoriam — Friend, Scientific Innovator and Leader Dr. Dale B. Schenk has Passed Away
DUBLIN, Ireland, Sept. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), announced today that its Co-founder, President and Chief Executive Officer, Dr. Dale B. Schenk, passed away this morning, after confronting his pancreatic cancer with the same courage, determination and
View HTML
Toggle Summary Prothena Outlines Phase 2 Development Strategy for PRX003
Investor conference call and webcast planned today at 4:30 PM ET DUBLIN, Ireland, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will
View HTML
Toggle Summary Prothena Announces President and CEO Dr. Dale B. Schenk to Take Medical Leave
DUBLIN, Ireland, Sept. 26, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that its President and Chief Executive Officer Dale
View HTML
Toggle Summary Prothena to Host Update on PRX003 Phase 2 Development Strategy
DUBLIN, Ireland, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its management team will discuss the
View HTML
Toggle Summary Prothena Announces Appointment of Gene G. Kinney as Chief Operating Officer
DUBLIN, Ireland, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced the promotion of Gene G.
View HTML
Toggle Summary Prothena to Participate in Upcoming September Investor Conferences
DUBLIN, Ireland, Aug. 30, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development, and commercialization of novel protein immunotherapies, today announced that members of its senior management team will
View HTML
Toggle Summary Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update
Net cash used in operating and investing activities was $32.3 million in the second quarter and $57.7 million for the first six months of 2016; strong quarter-end cash and restricted cash position of $447.0 million supports advancement of multiple clinical development programs Presented new
View HTML
Toggle Summary Prothena to Participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference
DUBLIN, Ireland, July 06, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will
View HTML
Toggle Summary Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis
New data from Phase 1/2 dose-escalation (n=27) and expansion (n=42) study show best response rates in total cardiac- and renal- evaluable patients of 53% and 63%, respectively, that are consistent with those previously published in the Journal of Clinical Oncology Improvement of peripheral
View HTML
Toggle Summary Prothena to Present at 15th International Symposium on Amyloidosis Showcasing Broad Commitment to Advancing New Therapies for Systemic Amyloidoses
New clinical data to be presented from Phase 1/2 dose-escalation and expansion trial of NEOD001 for the potential treatment of AL amyloidosis Presentations to highlight data from clinical, preclinical and quality-of-life studies Investor webcast planned for July 5, 2016 at 10:30 AM EDT DUBLIN,
View HTML
Toggle Summary Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases
All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteers Neutralization of Th17 cells of greater than 95 percent and statistically significant  dose-dependent duration of MCAM downregulation observed at
View HTML